eligibility_summary
Eligible: CD20+ DLBCL—untreated (IPI 3–5 in Part 1, ≥2 in Part 2) or R/R (Part 1A)—with measurable disease, ECOG ≤2, life expectancy ≥12 months, and adequate organ function. Exclude: CNS lymphoma/involvement, other active malignancy/serious illness, ≥Grade 3 neuropathy, prior anti‑lymphoma therapy (except R/R or transformed FL), recent investigational therapy/surgery/transplant/radiation, study-drug hypersensitivity, and active infections (e.g., COVID‑19, HIV, HBV/HCV). Per protocol.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3, open-label, randomized OLYMPIA-3 compares ODRO-CHOP (odronextamab + CHOP) vs R-CHOP in previously untreated DLBCL (dose-finding Part 1, efficacy Part 2). Odronextamab (REGN1979) is an anti-CD20×anti-CD3 bispecific IgG T‑cell engager that binds CD20 on B cells and CD3 on T cells, redirecting cytotoxic T cells to kill malignant CD20+ B cells. Comparator rituximab is a chimeric anti‑CD20 monoclonal antibody that depletes B cells via ADCC, CDC, and apoptosis. CHOP: cyclophosphamide (alkylating DNA cross-linker), doxorubicin (anthracycline/topoisomerase II inhibitor), vincristine (vinca alkaloid microtubule inhibitor), prednisone/prednisolone (glucocorticoid lympholytic). Targets/pathways: CD20+ B cells, T‑cell activation via CD3/immune synapse, DNA damage/crosslinking, topoisomerase II inhibition, mitotic spindle disruption, glucocorticoid receptor–mediated apoptosis.